Cardiome Pharma (COM) EPS Estimated At $-0.21; 4 Analysts Covering Medivation (MDVN)

October 13, 2017 - By Darrin Black

Analysts expect Cardiome Pharma Corp (TSE:COM) to report $-0.21 EPS on November, 6.They anticipate $0.03 EPS change or 12.50% from last quarter’s $-0.24 EPS. After having $-0.35 EPS previously, Cardiome Pharma Corp’s analysts see -40.00% EPS growth. About 31,618 shares traded or 99.58% up from the average. Cardiome Pharma Corp (TSE:COM) has 0.00% since October 13, 2016 and is . It has underperformed by 16.70% the S&P500.

Among 20 analysts covering Medivation Inc (NASDAQ:MDVN), 4 have Buy rating, 0 Sell and 16 Hold. Therefore 20% are positive. Medivation Inc had 48 analyst reports since July 31, 2015 according to SRatingsIntel. Maxim Group maintained it with “Buy” rating and $54 target in Tuesday, November 10 report. The company was maintained on Wednesday, August 10 by Credit Suisse. The firm earned “Hold” rating on Monday, August 22 by Brean Capital. The stock of Medivation Inc (NASDAQ:MDVN) earned “Hold” rating by Maxim Group on Tuesday, August 23. On Friday, May 6 the stock rating was upgraded by Citigroup to “Buy”. The firm has “Buy” rating given on Wednesday, August 26 by Maxim Group. On Monday, September 28 the stock rating was maintained by Maxim Group with “Buy”. Citigroup downgraded Medivation Inc (NASDAQ:MDVN) on Monday, August 22 to “Neutral” rating. As per Monday, August 10, the company rating was maintained by Brean Capital. The firm has “Sector Perform” rating given on Friday, November 6 by RBC Capital Markets. See Medivation Inc (NASDAQ:MDVN) latest ratings:

Medivation, Inc. is a biopharmaceutical company. The company has market cap of $13.52 billion. The Firm is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. It currently has negative earnings. The Company, in collaboration with Astellas Pharma, Inc. , has one commercial product, XTANDI (enzalutamide) capsules (XTANDI).

It is down 0.00% since October 13, 2016 and is . It has underperformed by 16.70% the S&P500.

Cardiome Pharma Corp. is a specialty pharmaceutical company. The company has market cap of $83.92 million. The Firm is engaged in the development and commercialization of cardiovascular therapies for heart disease. It currently has negative earnings. The Company’s divisions are Europe and Rest of World.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com